

Acknowledgement to Referees

© Springer Nature Switzerland AG 2021

Dear Reader,

Welcome to the final issue of *Targeted Oncology* for 2021.

I wish to reflect on this year's achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.

In 2021, over 70 articles have been published. The most popular of these in terms of downloads from SpringerLink have been:

- [An Overview of PARP Inhibitors for the Treatment of Breast Cancer](#)
- [Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice](#)
- [Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib](#)
- [Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study](#)
- [Vaccine Therapies for Cancer: Then and Now](#)
- [Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA](#)
- [TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting](#)
- [Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis](#)
- [Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF \$\beta\$ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase I Cohort in Asia](#)
- [Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives](#)

The high quality of content published in *Targeted Oncology* has been reflected in the most recent impact factor of 4.493 and CiteScore™ of 7.3. Further, *Targeted Oncology* has published content in a timely manner, with an average time from submission to first decision of 15 days.

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in *Targeted Oncology* over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for *Targeted Oncology* in the last 12 months:

Muhammad Zubair Afzal, USA
 Thierry Alcindor, Canada
 Lawrence Andrews, USA
 Kazuhiro Araki, Japan
 Hugo Arasanz Esteban, Spain
 Rebecca Arend, USA
 Jean Auliac, France
 Kyaw Aung, USA
 Aristotelis Bamias, Greece
 Mark Barok, Finland
 Viviana Bazan, Italy
 Bertram Bengsch, Germany
 Eric Bernicker, USA
 Jan Bieńkiewicz, Poland
 Annalen Bleckmann, Germany
 Burkhard Brandt, Germany
 Virginia Calvo, Spain
 John Carucci, USA
 Aude Charbonnier, France
 Aman Chauhan, USA
 Chao-Hua Chiu, Taiwan, Republic of China
 Joanne Chiu, Hong Kong, China
 Shih-Feng Cho, Taiwan, Republic of China
 Petros Christopoulos, Germany
 Pawel Chrom, Poland
 Pippa Corrie, UK
 Kristof Cuppens, Belgium
 Nancy Davis, USA
 Theo de Reijke, The Netherlands
 Giovan Giuseppe Di Costanzo, Italy
 Valérie Dutoit, Switzerland
 Camille Evrard, France
 Conrad Fernandez, Canada
 Steven Fling, USA
 Elisa Fontana, UK
 Christos Fountzilas, USA
 Masahide Fukudo, Japan
 Thilo Gambichler, Germany
 Pere Gascon, Spain
 Prafull Ghatage, Canada
 Paola Ghione, USA
 Valerie Glutsch, Germany
 María Teresa Gómez-Casares, Spain
 Thomas Graillon, France
 Alastair Greystoke, UK
 Xiuwen Guan, China
 David Guttery, UK
 Jun Hanaoka, Japan
 Simon Harrison, Australia
 Alain Hendlisz, Belgium
 Cinta Hierro, Spain
 John Hilton, Canada
 Maximilian J. Hochmair, Austria
 Sarah A. Holstein, USA
 Chih-Hung Hsu, Taiwan, Republic of China
 Harun Ilhan, Germany
 Gino In, USA
 Hiroki Ishihara, Japan
 Eiji Iwama, Japan
 Stefan Kasper, Germany
 Mustafa Khasraw, USA
 Dennis Kim, Canada
 Kyung Bo Kim, USA
 Sang-We Kim, Republic of Korea
 Heinz-Josef Klumpen, The Netherlands
 Scott Chih-Hsi Kuo, Taiwan, Republic of China
 Teiji Kuzuya, Japan
 Ulrik Lassen, Denmark
 Jae Cheol Lee, Republic of Korea
 Jeeyun Lee, Republic of Korea
 Joycelyn Lee, Singapore
 Konstantinos Leventakos, USA
 Bora Lim, USA
 Chia-Chi Lin, Taiwan, Republic of China
 Nan Lin, USA
 Gabriella Liskay, Hungary
 Xue-Qun Luo, China
 Susanne Malander, Sweden
 Steven Maron, USA
 Koji Matsuo, USA
 Gianluca Mauri, Italy
 Felicity May, UK
 Bradley McGregor, USA
 Pam McKay, UK
 Joseph Mikhael, USA
 Maria Carmen Mir, Spain
 Alberto Montero, USA
 Sarbajit Mukherjee, USA
 Aiko Nagayama, Japan
 Jayakumar Nair, USA
 Masahito Nakano, Japan
 Beatrice Nardone, USA
 Takahito Negishi, Japan
 Matthew Chau Hsien Ng, Singapore
 Shin Nishio, Japan
 Noboru Numao, Japan
 Shuntaro Obi, Japan
 Scott Okuno, USA
 L'Houcine Ouafik, France
 Tejas Patil, USA
 Patricia Pautier, France

Tyrel Phillips, USA	Chunxia Su, China
Camelia Quek, Australia	Kenichi Suda, USA
Renju Raj, USA	Daisuke Takahari, Japan
Emanuel Raschi, Italy	Junko Tanizaki, Japan
Isabelle Ray-Coquard, France	Tetsu Tomonari, Japan
Joshua Richter, USA	Nikolaos Tsoukalas, Greece
Lorenza Rimassa, Italy	Akihiro Tsuboi, Japan
Daniele Rossini, Italy	Hiroshi Ureshino, Japan
Eduard Roussel, Belgium	Anke van den Berg, The Netherlands
Piotr Rutkowski, Poland	Brian van Tine, USA
Kazutaka Saito, Japan	Naveen Vasudev, UK
Martin Salzmann, Germany	Kathelijn Versteeg, The Netherlands
Hironaga Satake, Japan	Nikolaus Wagner, Germany
Yuki Sato, Japan	Yufeng Wang, USA
Maria Scavo, Italy	Muzamil Want, USA
Hans-Ulrich Schildhaus, Germany	David Waterhouse, USA
Manuela Schmidinger, Austria	Marcel Wiesweg, Germany
Scott Schuetze, USA	Min Yan, China
Cesar Serrano, Spain	Rinat Yerushalmi, Israel
Neal Shore, USA	Kan Yoenmori, Japan
Darren Sigal, USA	Changhoon Yoo, Republic of Korea
Nicola Silvestris, Italy	Tatsuya Yoshida, Japan
Hiroshi Soda, Japan	Tian Zhang, USA
Corey Speers, USA	David Ziegler, Australia
Srikala Sridhar, Canada	

I also very grateful to the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy, and processes:

James Armitage, University of Nebraska Medical Center, Omaha, NE, USA
 James Berenson, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA
 Jean-Yves Blay, University Claude Bernard Lyon I, Lyon, France
 Tomas Buchler, Charles University and Thomayer Hospital, Prague, Czech Republic
 Ann-Lii Cheng, National Taiwan University, Taipei, Taiwan, Republic of China
 Fortunato Ciardiello, Second University of Naples, Naples, Italy
 Jayesh Desai, The Royal Melbourne Hospital, Melbourne, VIC, Australia
 Sandrine Faivre, Beaujon University Hospital, Clichy, France
 Giuseppe Giaccone, Weill Cornell Medicine, New York, NY, USA
 Petros Grivas, University of Washington, Seattle, WA, USA
 Balazs Halmos, Montefiore Medical Center, New York, NY, USA
 Gabriel Hortobagyi, Houston, TX, USA
 Christian Jackisch, Sana Klinikum, Offenbach, Germany
 V. Craig Jordan, MD Anderson, Houston, Texas, USA
 John Kirkwood, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
 Heinz-Josef Lenz, University of Southern California, Los Angeles, CA, USA
 Teresa Macarulla, Vall d'Hebron University Hospital, Barcelona, Spain
 Mark McKeage, University of Auckland, Auckland, New Zealand
 Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
 Monica Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
 Jean-François Morère, Hôpital Avicenne, Paris-Nord, France
 Athanasios Papavassiliou, National and Kapodistrian University of Athens, Athens, Greece
 Camilo Porta, IRCCS San Matteo University Hospital Foundation, Pavia, Italy
 Timothy Price, The Queen Elizabeth Hospital, Adelaide, SA, Australia

Shukui Qin, Chinese Society of Clinical Oncology, Nanjing, China
Eric Raymond, Groupe Hospitalier Paris Saint-Joseph, Paris, France
Richard Riedel, Duke University, Durham, NC, USA
Olivier Rixe, Quantum Santa Fe, Santa Fe, NM, USA
Helen Rizos, Macquarie University, North Ryde, NSW, Australia
Nicole Shonka, University of Nebraska Medical Center, Omaha, NE, USA
Denis Soulières, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
Yu Sunakawa, St. Marianna University School of Medicine, Kawasaki, Japan
Eric Van Cutsem, University Hospitals Leuven, Leuven, Belgium

In terms of other important company initiatives, the Springer Nature 'Sustainable Development Goals (SDG) Programme' is aiming to connect researchers who are tackling the world's toughest challenges with practitioners in policy and business, while the 'Women in Science' initiative aims to help empower more women scientists to achieve scientific excellence. Finally, I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet, and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.

Returning to *Targeted Oncology*, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of *Targeted Oncology* over the coming year.

I thank you for your continued support.

With best wishes,
Martin Chopra